Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 240

1.

Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.

Moreno L, Casanova M, Chisholm JC, Berlanga P, Chastagner PB, Baruchel S, Amoroso L, Gallego Melcón S, Gerber NU, Bisogno G, Fagioli F, Geoerger B, Glade Bender JL, Aerts I, Bergeron C, Hingorani P, Elias I, Simcock M, Ferrara S, Le Bruchec Y, Slepetis R, Chen N, Vassal G.

Eur J Cancer. 2018 Sep;100:27-34. doi: 10.1016/j.ejca.2018.05.002. Epub 2018 Jun 21.

PMID:
29936064
2.

Author Correction: The landscape of genomic alterations across childhood cancers.

Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, Johann PD, Balasubramanian GP, Segura-Wang M, Brabetz S, Bender S, Hutter B, Sturm D, Pfaff E, Hübschmann D, Zipprich G, Heinold M, Eils J, Lawerenz C, Erkek S, Lambo S, Waszak S, Blattmann C, Borkhardt A, Kuhlen M, Eggert A, Fulda S, Gessler M, Wegert J, Kappler R, Baumhoer D, Burdach S, Kirschner-Schwabe R, Kontny U, Kulozik AE, Lohmann D, Hettmer S, Eckert C, Bielack S, Nathrath M, Niemeyer C, Richter GH, Schulte J, Siebert R, Westermann F, Molenaar JJ, Vassal G, Witt H, Burkhardt B, Kratz CP, Witt O, van Tilburg CM, Kramm CM, Fleischhack G, Dirksen U, Rutkowski S, Frühwald M, von Hoff K, Wolf S, Klingebiel T, Koscielniak E, Landgraf P, Koster J, Resnick AC, Zhang J, Liu Y, Zhou X, Waanders AJ, Zwijnenburg DA, Raman P, Brors B, Weber UD, Northcott PA, Pajtler KW, Kool M, Piro RM, Korbel JO, Schlesner M, Eils R, Jones DTW, Lichter P, Chavez L, Zapatka M, Pfister SM; ICGC PedBrain-Seq Project; ICGC MMML-Seq Project.

Nature. 2018 Jul;559(7714):E10. doi: 10.1038/s41586-018-0167-2.

PMID:
29875405
3.

Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial.

Mackay A, Burford A, Molinari V, Jones DTW, Izquierdo E, Brouwer-Visser J, Giangaspero F, Haberler C, Pietsch T, Jacques TS, Figarella-Branger D, Rodriguez D, Morgan PS, Raman P, Waanders AJ, Resnick AC, Massimino M, Garrè ML, Smith H, Capper D, Pfister SM, Würdinger T, Tam R, Garcia J, Thakur MD, Vassal G, Grill J, Jaspan T, Varlet P, Jones C.

Cancer Cell. 2018 May 14;33(5):829-842.e5. doi: 10.1016/j.ccell.2018.04.004.

4.

Accelerating Pediatric Cancer Drug Development: Challenges and Opportunities for Pediatric Master Protocols.

Khan T, Stewart M, Blackman S, Rousseau R, Donoghue M, Cohen K, Seibel N, Fleury M, Benettaib B, Malik R, Vassal G, Reaman G.

Ther Innov Regul Sci. 2018 Jan 1:2168479018774533. doi: 10.1177/2168479018774533. [Epub ahead of print]

PMID:
29759018
5.

10-year report on the European Paediatric Regulation and its impact on new drugs for children's cancers.

Pearson AD, Heenen D, Kearns PR, Goeres A, Marshall LV, Blanc P, Vassal G.

Lancet Oncol. 2018 Mar;19(3):285-287. doi: 10.1016/S1470-2045(18)30105-0. No abstract available.

PMID:
29508745
6.

The landscape of genomic alterations across childhood cancers.

Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, Johann PD, Balasubramanian GP, Segura-Wang M, Brabetz S, Bender S, Hutter B, Sturm D, Pfaff E, Hübschmann D, Zipprich G, Heinold M, Eils J, Lawerenz C, Erkek S, Lambo S, Waszak S, Blattmann C, Borkhardt A, Kuhlen M, Eggert A, Fulda S, Gessler M, Wegert J, Kappler R, Baumhoer D, Burdach S, Kirschner-Schwabe R, Kontny U, Kulozik AE, Lohmann D, Hettmer S, Eckert C, Bielack S, Nathrath M, Niemeyer C, Richter GH, Schulte J, Siebert R, Westermann F, Molenaar JJ, Vassal G, Witt H; ICGC PedBrain-Seq Project; ICGC MMML-Seq Project, Burkhardt B, Kratz CP, Witt O, van Tilburg CM, Kramm CM, Fleischhack G, Dirksen U, Rutkowski S, Frühwald M, von Hoff K, Wolf S, Klingebiel T, Koscielniak E, Landgraf P, Koster J, Resnick AC, Zhang J, Liu Y, Zhou X, Waanders AJ, Zwijnenburg DA, Raman P, Brors B, Weber UD, Northcott PA, Pajtler KW, Kool M, Piro RM, Korbel JO, Schlesner M, Eils R, Jones DTW, Lichter P, Chavez L, Zapatka M, Pfister SM.

Nature. 2018 Mar 15;555(7696):321-327. doi: 10.1038/nature25480. Epub 2018 Feb 28. Erratum in: Nature. 2018 Jul;559(7714):E10.

PMID:
29489754
7.

Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma.

Grill J, Massimino M, Bouffet E, Azizi AA, McCowage G, Cañete A, Saran F, Le Deley MC, Varlet P, Morgan PS, Jaspan T, Jones C, Giangaspero F, Smith H, Garcia J, Elze MC, Rousseau RF, Abrey L, Hargrave D, Vassal G.

J Clin Oncol. 2018 Apr 1;36(10):951-958. doi: 10.1200/JCO.2017.76.0611. Epub 2018 Feb 7.

PMID:
29412784
8.

Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE.

Gaspar N, Marshall LV, Binner D, Herold R, Rousseau R, Blanc P, Capdeville R, Carleer J, Copland C, Kerloeguen Y, Norga K, Pacaud L, Sevaux MA, Spadoni C, Sterba J, Ligas F, Taube T, Uttenreuther-Fischer M, Chioato S, O'Connell MA, Geoerger B, Blay JY, Soria JC, Kaye S, Wulff B, Brugières L, Vassal G, Pearson ADJ; Members of Working Group 1 of the Paediatric Platform of ACCELERATE.

Ann Oncol. 2018 Mar 1;29(3):766-771. doi: 10.1093/annonc/mdy002. No abstract available.

9.

Outcome of children and adolescents with central nervous system tumors in phase I trials.

Carceller F, Bautista F, Jiménez I, Hladun-Álvaro R, Giraud C, Bergamaschi L, Dandapani M, Aerts I, Doz F, Frappaz D, Casanova M, Morland B, Hargrave DR, Vassal G, Pearson ADJ, Geoerger B, Moreno L, Marshall LV.

J Neurooncol. 2018 Mar;137(1):83-92. doi: 10.1007/s11060-017-2698-z. Epub 2017 Dec 13.

PMID:
29236237
10.

Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma.

Rigaud C, Abbou S, Minard-Colin V, Geoerger B, Scoazec JY, Vassal G, Jaff N, Heuberger L, Valteau-Couanet D, Brugieres L.

Pediatr Blood Cancer. 2018 Apr;65(4). doi: 10.1002/pbc.26902. Epub 2017 Nov 28. No abstract available.

PMID:
29193772
11.

Roles of Clinical Research Networks in Pediatric Drug Development.

Turner MA, Attar S, de Wildt SN, Vassal G, Mangiarini L, Giaquinto C.

Clin Ther. 2017 Oct;39(10):1939-1948. doi: 10.1016/j.clinthera.2017.09.001. Epub 2017 Sep 22. Review.

PMID:
28943118
12.

Orphan Drug Regulation: A missed opportunity for children and adolescents with cancer.

Vassal G, Kearns P, Blanc P, Scobie N, Heenen D, Pearson A.

Eur J Cancer. 2017 Oct;84:149-158. doi: 10.1016/j.ejca.2017.07.021. Epub 2017 Sep 4.

PMID:
28818704
13.

Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.

Harttrampf AC, Lacroix L, Deloger M, Deschamps F, Puget S, Auger N, Vielh P, Varlet P, Balogh Z, Abbou S, Allorant A, Valteau-Couanet D, Sarnacki S, Gamiche-Rolland L, Meurice G, Minard-Colin V, Grill J, Brugieres L, Dufour C, Gaspar N, Michiels S, Vassal G, Soria JC, Geoerger B.

Clin Cancer Res. 2017 Oct 15;23(20):6101-6112. doi: 10.1158/1078-0432.CCR-17-0381. Epub 2017 Jul 21.

PMID:
28733441
14.

From class waivers to precision medicine in paediatric oncology.

Pearson ADJ, Pfister SM, Baruchel A, Bourquin JP, Casanova M, Chesler L, Doz F, Eggert A, Geoerger B, Jones DTW, Kearns PR, Molenaar JJ, Morland B, Schleiermacher G, Schulte JH, Vormoor J, Marshall LV, Zwaan CM, Vassal G; Executive and Biology Committees of the Innovative Therapies for Children with Cancer European Consortium.

Lancet Oncol. 2017 Jul;18(7):e394-e404. doi: 10.1016/S1470-2045(17)30442-4. Review.

PMID:
28677575
15.

Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.

Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, Schulte JH, De Preter K, Molenaar J, Schramm A, Eilers M, Van Maerken T, Johnsen JI, Garrett M, George SL, Tweddle DA, Kogner P, Berthold F, Koster J, Barone G, Tucker ER, Marshall L, Herold R, Sterba J, Norga K, Vassal G, Pearson AD.

Expert Opin Drug Discov. 2017 Aug;12(8):801-811. doi: 10.1080/17460441.2017.1340269. Epub 2017 Jun 26. Review.

PMID:
28604107
16.

Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.

Moreno L, Pearson ADJ, Paoletti X, Jimenez I, Geoerger B, Kearns PR, Zwaan CM, Doz F, Baruchel A, Vormoor J, Casanova M, Pfister SM, Morland B, Vassal G; Innovative Therapies for Children with Cancer (ITCC) Consortium.

Nat Rev Clin Oncol. 2017 Aug;14(8):497-507. doi: 10.1038/nrclinonc.2017.59. Epub 2017 May 16. Review.

PMID:
28508875
17.

Genomic diagnostics leading to the identification of a TFG-ROS1 fusion in a child with possible atypical meningioma.

Rossing M, Yde CW, Sehested A, Østrup O, Scheie D, Dangouloff-Ros V, Geoerger B, Vassal G, Nysom K.

Cancer Genet. 2017 Apr;212-213:32-37. doi: 10.1016/j.cancergen.2017.03.005. Epub 2017 Mar 22.

18.

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.

Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel-Vinay S, Loriot Y, Even C, Breuskin I, Auger N, Job B, De Baere T, Deschamps F, Vielh P, Scoazec JY, Lazar V, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F, Soria JC.

Cancer Discov. 2017 Jun;7(6):586-595. doi: 10.1158/2159-8290.CD-16-1396. Epub 2017 Apr 1.

19.

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

Ladenstein R, Pötschger U, Pearson ADJ, Brock P, Luksch R, Castel V, Yaniv I, Papadakis V, Laureys G, Malis J, Balwierz W, Ruud E, Kogner P, Schroeder H, de Lacerda AF, Beck-Popovic M, Bician P, Garami M, Trahair T, Canete A, Ambros PF, Holmes K, Gaze M, Schreier G, Garaventa A, Vassal G, Michon J, Valteau-Couanet D; SIOP Europe Neuroblastoma Group (SIOPEN).

Lancet Oncol. 2017 Apr;18(4):500-514. doi: 10.1016/S1470-2045(17)30070-0. Epub 2017 Mar 2.

PMID:
28259608
20.

Busulfan after HSCT in children and young adults.

Paci A, Poinsignon V, Broutin S, Mir O, Vassal G.

Lancet Haematol. 2017 Mar;4(3):e103. doi: 10.1016/S2352-3026(16)30189-2. No abstract available.

PMID:
28257751
21.

The right to be forgotten: a change in access to insurance and loans after childhood cancer?

Dumas A, Allodji R, Fresneau B, Valteau-Couanet D, El-Fayech C, Pacquement H, Laprie A, Nguyen TD, Bondiau PY, Diallo I, Guibout C, Rubino C, Haddy N, Oberlin O, Vassal G, de Vathaire F.

J Cancer Surviv. 2017 Aug;11(4):431-437. doi: 10.1007/s11764-017-0600-9. Epub 2017 Jan 27.

PMID:
28130711
22.

ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review.

Andritsch E, Beishon M, Bielack S, Bonvalot S, Casali P, Crul M, Delgado Bolton R, Donati DM, Douis H, Haas R, Hogendoorn P, Kozhaeva O, Lavender V, Lovey J, Negrouk A, Pereira P, Roca P, de Lempdes GR, Saarto T, van Berck B, Vassal G, Wartenberg M, Yared W, Costa A, Naredi P.

Crit Rev Oncol Hematol. 2017 Feb;110:94-105. doi: 10.1016/j.critrevonc.2016.12.002. Epub 2016 Dec 8. Review.

23.

Dual inhibition using cabozantinib overcomes HGF/MET signaling mediated resistance to pan-VEGFR inhibition in orthotopic and metastatic neuroblastoma tumors.

Daudigeos-Dubus E, Le Dret L, Bawa O, Opolon P, Vievard A, Villa I, Bosq J, Vassal G, Geoerger B.

Int J Oncol. 2017 Jan;50(1):203-211. doi: 10.3892/ijo.2016.3792. Epub 2016 Dec 6.

PMID:
27922668
24.

Autophagy is associated with chemoresistance in neuroblastoma.

Belounis A, Nyalendo C, Le Gall R, Imbriglio TV, Mahma M, Teira P, Beaunoyer M, Cournoyer S, Haddad E, Vassal G, Sartelet H.

BMC Cancer. 2016 Nov 15;16(1):891.

25.

Access to loan-related insurance for French cancer survivors.

Dumas A, De Vathaire F, Vassal G.

Lancet Oncol. 2016 Oct;17(10):1354-1356. doi: 10.1016/S1470-2045(16)30452-1. No abstract available.

PMID:
27733259
26.

Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study.

Carceller F, Bautista FJ, Jiménez I, Hladun-Álvaro R, Giraud C, Bergamaschi L, Dandapani M, Aerts I, Doz F, Frappaz D, Casanova M, Morland B, Hargrave DR, Marshall LV, Vassal G, Pearson AD, Geoerger B, Moreno L.

Eur J Cancer. 2016 Nov;67:130-140. doi: 10.1016/j.ejca.2016.08.008. Epub 2016 Sep 21.

PMID:
27662616
27.

Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.

Moreno L, Rubie H, Varo A, Le Deley MC, Amoroso L, Chevance A, Garaventa A, Gambart M, Bautista F, Valteau-Couanet D, Geoerger B, Vassal G, Paoletti X, Pearson AD.

Pediatr Blood Cancer. 2017 Jan;64(1):25-31. doi: 10.1002/pbc.26192. Epub 2016 Aug 24.

PMID:
27555472
28.

The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report.

Kager L, Whelan J, Dirksen U, Hassan B, Anninga J, Bennister L, Bovée JVMG, Brennan B, Broto JM, Brugières L, Cleton-Jansen AM, Copland C, Dutour A, Fagioli F, Ferrari S, Fiocco M, Fleuren E, Gaspar N, Gelderblom H, Gerrand C, Gerß J, Gonzato O, van der Graaf W, Hecker-Nolting S, Herrero-Martín D, Klco-Brosius S, Kovar H, Ladenstein R, Lancia C, LeDeley MC, McCabe MG, Metzler M, Myklebost O, Nathrath M, Picci P, Potratz J, Redini F, Richter GHS, Reinke D, Rutkowski P, Scotlandi K, Strauss S, Thomas D, Tirado OM, Tirode F, Vassal G, Bielack SS.

Clin Sarcoma Res. 2016 Mar 16;6:3. doi: 10.1186/s13569-016-0043-5. eCollection 2016.

29.

Implementation of mechanism of action biology-driven early drug development for children with cancer.

Pearson AD, Herold R, Rousseau R, Copland C, Bradley-Garelik B, Binner D, Capdeville R, Caron H, Carleer J, Chesler L, Geoerger B, Kearns P, Marshall LV, Pfister SM, Schleiermacher G, Skolnik J, Spadoni C, Sterba J, van den Berg H, Uttenreuther-Fischer M, Witt O, Norga K, Vassal G; Members of Working Group 1 of the Paediatric Platform of ACCELERATE.

Eur J Cancer. 2016 Jul;62:124-31. doi: 10.1016/j.ejca.2016.04.001. Epub 2016 May 31. Review.

PMID:
27258969
30.

European Survey on Standards of Care in paediatric oncology centres.

Kowalczyk JR, Samardakiewicz M, Pritchard-Jones K, Ladenstein R, Essiaf S, Fitzgerald E, Petrarulo G, Vassal G.

Eur J Cancer. 2016 Jul;61:11-9. doi: 10.1016/j.ejca.2016.03.073. Epub 2016 Apr 28.

PMID:
27131152
31.

Educational and occupational outcomes of childhood cancer survivors 30 years after diagnosis: a French cohort study.

Dumas A, Berger C, Auquier P, Michel G, Fresneau B, Sètchéou Allodji R, Haddy N, Rubino C, Vassal G, Valteau-Couanet D, Thouvenin-Doulet S, Casagranda L, Pacquement H, El-Fayech C, Oberlin O, Guibout C, de Vathaire F.

Br J Cancer. 2016 Apr 26;114(9):1060-8. doi: 10.1038/bjc.2016.62.

32.

Iron Overload Exacerbates Busulfan-Melphalan Toxicity Through a Pharmacodynamic Interaction in Mice.

Bouligand J, Richard C, Valteau-Couanet D, Orear C, Mercier L, Kessari R, Simonnard N, Munier F, Daudigeos-Dubus E, Tou B, Opolon P, Deroussent A, Paci A, Vassal G.

Pharm Res. 2016 Aug;33(8):1913-22. doi: 10.1007/s11095-016-1927-z. Epub 2016 Apr 18.

PMID:
27091031
33.

Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.

Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F, Kool M, Dufour C, Vassal G, Milde T, Witt O, von Hoff K, Pietsch T, Northcott PA, Gajjar A, Robinson GW, Padovani L, André N, Massimino M, Pizer B, Packer R, Rutkowski S, Pfister SM, Taylor MD, Pomeroy SL.

Acta Neuropathol. 2016 Jun;131(6):821-31. doi: 10.1007/s00401-016-1569-6. Epub 2016 Apr 4. Review.

34.

Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01).

Tacher V, Le Deley MC, Hollebecque A, Deschamps F, Vielh P, Hakime A, Ileana E, Abedi-Ardekani B, Charpy C, Massard C, Rosellini S, Gajda D, Celebic A, Ferté C, Ngo-Camus M, Gouissem S, Koubi-Pick V, Andre F, Vassal G, Deandreis D, Lacroix L, Soria JC, De Baère T.

Eur J Cancer. 2016 May;59:79-89. doi: 10.1016/j.ejca.2016.02.006. Epub 2016 Mar 24.

PMID:
27017289
35.

Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients.

Deutsch E, Haie-Meder C, Bayar MA, Mondini M, Laporte M, Mazeron R, Adam J, Varga A, Vassal G, Magné N, Chargari C, Lanoy E, Pautier P, Levy A, Soria JC.

Oncotarget. 2016 May 3;7(18):25549-57. doi: 10.18632/oncotarget.8224.

36.

Equal access to innovative therapies and precision cancer care.

Buzyn A, Blay JY, Hoog-Labouret N, Jimenez M, Nowak F, Deley MC, Pérol D, Cailliot C, Raynaud J, Vassal G.

Nat Rev Clin Oncol. 2016 Jun;13(6):385-93. doi: 10.1038/nrclinonc.2016.31. Epub 2016 Mar 22. Review.

PMID:
27000960
37.

Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.

Abbou S, Lanvers-Kaminsky C, Daudigeos-Dubus E, LE Dret L, Laplace-Builhe C, Molenaar J, Vassal G, Geoerger B; within the ITCC Biology and Preclinical Evaluation Committee.

Anticancer Res. 2016 Feb;36(2):599-609.

PMID:
26851014
38.

Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.

Benderra MA, Aspeslagh S, Postel-Vinay S, Bigot L, De Baere T, Loriot Y, Lacroix L, Massard C, Vassal G, André F, Soria JC.

J Thorac Oncol. 2016 Feb;11(2):e21-3. doi: 10.1016/j.jtho.2015.08.001. Epub 2015 Dec 18. No abstract available.

39.

Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.

Jovelet C, Ileana E, Le Deley MC, Motté N, Rosellini S, Romero A, Lefebvre C, Pedrero M, Pata-Merci N, Droin N, Deloger M, Massard C, Hollebecque A, Ferté C, Boichard A, Postel-Vinay S, Ngo-Camus M, De Baere T, Vielh P, Scoazec JY, Vassal G, Eggermont A, André F, Soria JC, Lacroix L.

Clin Cancer Res. 2016 Jun 15;22(12):2960-8. doi: 10.1158/1078-0432.CCR-15-2470. Epub 2016 Jan 12.

40.

Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma.

Regairaz M, Munier F, Sartelet H, Castaing M, Marty V, Renauleaud C, Doux C, Delbé J, Courty J, Fabre M, Ohta S, Vielh P, Michiels S, Valteau-Couanet D, Vassal G.

Am J Pathol. 2016 Feb;186(2):435-45. doi: 10.1016/j.ajpath.2015.10.016. Epub 2015 Dec 12.

PMID:
26687816
41.

[Multidisciplinarity, education, and training in pediatric oncology-hematology].

Vassal G, Landman-Parker J, Baruchel A, Bergeron C, Rubie H, Coze C, Chastagner P, Leverger G, Bertrand Y, Valteau-Couanet D, Michon J, Couanet D, Rivière AM, Avenell D, Pérel Y, Doz F.

Arch Pediatr. 2015 Dec;22(12):1217-22. doi: 10.1016/j.arcped.2015.09.012. Epub 2015 Nov 18. Review. French.

PMID:
26604021
42.

Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.

Daudigeos-Dubus E, Le Dret L, Lanvers-Kaminsky C, Bawa O, Opolon P, Vievard A, Villa I, Pagès M, Bosq J, Vassal G, Zopf D, Geoerger B.

PLoS One. 2015 Nov 23;10(11):e0142612. doi: 10.1371/journal.pone.0142612. eCollection 2015.

43.

Nuclear localization of the caspase-3-cleaved form of p73 in anoikis.

Alsafadi S, Tourpin S, Bessoltane N, Salomé-Desnoulez S, Vassal G, André F, Ahomadegbe JC.

Oncotarget. 2016 Mar 15;7(11):12331-43. doi: 10.18632/oncotarget.6329.

44.

Will the revised class waiver list make it?

Vassal G, Blanc P, Copland C, Pearson A.

Lancet Oncol. 2015 Sep;16(9):e425-e426. doi: 10.1016/S1470-2045(15)00233-8. No abstract available.

PMID:
26370347
45.

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer.

Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, Batist G, Le Chevalier T, Morice P, Besse B, Vassal G, Mortlock A, Hansson J, Berindan-Neagoe I, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R.

Oncotarget. 2015 Jun 10;6(16):14139-52.

46.

Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.

Truffaux N, Philippe C, Paulsson J, Andreiuolo F, Guerrini-Rousseau L, Cornilleau G, Le Dret L, Richon C, Lacroix L, Puget S, Geoerger B, Vassal G, Östman A, Grill J.

Neuro Oncol. 2015 Jul;17(7):953-64. doi: 10.1093/neuonc/nou330. Epub 2014 Dec 21.

47.

Preactivated oxazaphosphorines designed for isophosphoramide mustard delivery as bulk form or nanoassemblies: synthesis and proof of concept.

Skarbek C, Lesueur LL, Chapuis H, Deroussent A, Pioche Durieu C, Daville A, Caron J, Rivard M, Martens T, Bertrand JR, Le Cam E, Vassal G, Couvreur P, Desmaele D, Paci A.

J Med Chem. 2015 Jan 22;58(2):705-17. doi: 10.1021/jm501224x. Epub 2014 Dec 23.

PMID:
25494842
48.

Inhibition of the NOTCH pathway using γ-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors.

Dantas-Barbosa C, Bergthold G, Daudigeos-Dubus E, Blockus H, Boylan JF, Ferreira C, Puget S, Abely M, Vassal G, Grill J, Geoerger B.

Anticancer Drugs. 2015 Mar;26(3):272-83. doi: 10.1097/CAD.0000000000000190.

PMID:
25486598
49.

Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.

Vassal G, Rousseau R, Blanc P, Moreno L, Bode G, Schwoch S, Schrappe M, Skolnik J, Bergman L, Bradley-Garelik MB, Saha V, Pearson A, Zwierzina H.

Eur J Cancer. 2015 Jan;51(2):218-24. doi: 10.1016/j.ejca.2014.10.029. Epub 2014 Nov 27.

50.

Patients in pediatric phase I and early phase II clinical oncology trials at Gustave Roussy: a 13-year center experience.

Bautista F, Di Giannatale A, Dias-Gastellier N, Fahd M, Valteau-Couanet D, Couanet D, Grill J, Brugières L, Dufour C, Gaspar N, Minard-Colin V, Kalifa C, Oberlin O, Patte C, Vassal G, Geoerger B.

J Pediatr Hematol Oncol. 2015 Mar;37(2):e102-10. doi: 10.1097/MPH.0000000000000237.

PMID:
25171452

Supplemental Content

Loading ...
Support Center